You are here: Home: BCU 9 | 2005: Editor's office
 
     
 

EDITOR
Neil Love, MD

ASSOCIATE EDITORS
Michelle Paley, MD
Richard Kaderman, PhD
Kathryn Ault Ziel, PhD

WRITERS
Lilliam Sklaver Poltorack
PharmD
Sally Bogert, RNC, WHCNP
Douglas Paley

CME DIRECTOR
Michelle Paley, MD

CONTENT VALIDATION
Margaret Peng

DIRECTOR, CREATIVE
AND COPY EDITING

Aura Herrmann

CREATIVE MANAGER
Fernando Rendina

SENIOR DESIGNER
Christina Brigham

DESIGN QUALITY
CONTROL DIRECTOR
Ben Belin

ASSOCIATE DESIGNER
Maria Schaefer

GRAPHIC DESIGNERS
Jason Cunnius
Tamara Dabney

PRODUCTION EDITOR
Alexis Oneca

COPY EDITORS
Joy Davis
Rosemary Hulce
Pat Morrissey/Havlin
Carol Peschke
Susan Petrone

PRODUCTION MANAGER
Patricia Kappes

AUDIO PRODUCTION
Frank Cesarano

TECHNICAL SERVICES
Arly Ledezma

WEB MASTER
John Ribeiro

EDITORIAL ASSISTANTS
Catherine Marshall
Patricia McWhorter
Christina Rodriguez
Tere Sosa
Ginelle Suarez

CONTACT INFORMATION:
Neil Love, MD

RESEARCH TO PRACTICE
One Biscayne Tower
2 South Biscayne Boulevard
Suite 3600
Miami, FL 33131
Fax: (305) 377-9998
Email: NLove@ResearchToPractice.net

FOR CME INFORMATION:
Melissa Vives,
Associate CME Administrator
Email: MVives@ResearchToPractice.net

This program was supported by education grants from Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Roche Laboratories Inc.

The audio tapes, compact discs, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

 
 
 
     
 
 


 
Editor’s Note:
Cheetos and raisins for dinner: The curse of Wilma and why a public sector that can’t figure out a way to get electricity to gas stations seems unlikely to
be victorious in the “war on cancer”
 
Harold J Burstein, MD, PhD
- Select publications
 
Charles L Vogel, MD
- Select publications
 
Eleftherios P Mamounas, MD, MPH
- Select publications
 
Journal Club

Breast Cancer Journal Club Notes

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Trastuzumab After Adjuvant Chemotherapy in HER2-Positive Breast Cancer

E2100: A Randomized Phase III Trial of Paclitaxel versus Paclitaxel Plus Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer

Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer (ABC) in Older Women

Fulvestrant versus Anastrozole for the Treatment of Advanced
Breast Carcinoma: A Prospectively Planned Combined Survival
Analysis of Two Multicenter Trials

Patterns of Care in Medical Oncology: A Case Survey Comparing Practices of Breast Cancer Investigators and General Oncologists — Section A: Adjuvant Endocrine Therapy

 

 
CME Information
Faculty Disclosures
Editor's Office